Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06322563
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-21
First Post:
2024-02-26
Brief Title:
Combination of LTC004 and Regorafenib to Treat Patients With AdvancedMetastatic CRC
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
An Open Single-arm Phase II Clinical Study Evaluating the Safety and Initial Efficacy of LTC004 in Combination With Regorafenib in the Treatment of Metastatic Colorectal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II clinical study to evaluate the safety tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC A safety introductory trial was conducted to receive LTC004 in combination with regorafenib before starting the formal trial After completing a 28-day safety assessment safety will be confirmed before entering the formal trial phase Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None